138 related articles for article (PubMed ID: 34875534)
1. A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells.
Kawano Y; Sasano T; Arima Y; Kushima S; Tsujita K; Matsuoka M; Hata H
Biochem Biophys Res Commun; 2022 Jan; 587():153-159. PubMed ID: 34875534
[TBL] [Abstract][Full Text] [Related]
2. JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification.
Sun W; Xie Z; Liu Y; Zhao D; Wu Z; Zhang D; Lv H; Tang S; Jin N; Jiang H; Tan M; Ding J; Luo C; Li J; Huang M; Geng M
Cancer Res; 2015 Nov; 75(22):4923-36. PubMed ID: 26483203
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cancer Metabolism Plasticity with JX06 Nanoparticles via Inhibiting PDK1 Combined with Metformin for Endometrial Cancer Patients with Diabetes.
Yang X; Cheng Y; Zhou J; Zhang L; Li X; Wang Z; Yin S; Zhai L; Huang T; Wu X; Shen B; Dong Y; Zhao L; Chi Y; Jia Y; Wang J; He Y; Dong X; Xiao H; Wang J
Adv Sci (Weinh); 2022 Mar; 9(8):e2104472. PubMed ID: 35064767
[TBL] [Abstract][Full Text] [Related]
4. Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by Reducing Pyruvate Dehydrogenase Kinase 1 Activity.
Kwak CH; Jin L; Han JH; Han CW; Kim E; Cho M; Chung TW; Bae SJ; Jang SB; Ha KT
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825675
[TBL] [Abstract][Full Text] [Related]
5. PDK1 inhibition is a novel therapeutic target in multiple myeloma.
Fujiwara S; Kawano Y; Yuki H; Okuno Y; Nosaka K; Mitsuya H; Hata H
Br J Cancer; 2013 Jan; 108(1):170-8. PubMed ID: 23321518
[TBL] [Abstract][Full Text] [Related]
6. Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
Zhang W; Zhang SL; Hu X; Tam KY
Eur J Pharm Sci; 2017 Dec; 110():93-100. PubMed ID: 28450154
[TBL] [Abstract][Full Text] [Related]
7. miR-128-3p contributes to mitochondrial dysfunction and induces apoptosis in glioma cells via targeting pyruvate dehydrogenase kinase 1.
Qu C; Yan C; Cao W; Li F; Qu Y; Guan K; Si C; Yu Z; Qu Z
IUBMB Life; 2020 Mar; 72(3):465-475. PubMed ID: 31828927
[TBL] [Abstract][Full Text] [Related]
8. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
9. Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib.
Sanchez WY; McGee SL; Connor T; Mottram B; Wilkinson A; Whitehead JP; Vuckovic S; Catley L
Br J Cancer; 2013 Apr; 108(8):1624-33. PubMed ID: 23531700
[TBL] [Abstract][Full Text] [Related]
10. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 regulates glycolysis in nasopharyngeal carcinoma cells through PDK1.
Yang Q; Wu F; Zhang Y; Wang R
J Cell Mol Med; 2022 Jul; 26(13):3783-3796. PubMed ID: 35656815
[TBL] [Abstract][Full Text] [Related]
12. Blocking circ-CNST suppresses malignant behaviors of osteosarcoma cells and inhibits glycolysis through circ-CNST-miR-578-LDHA/PDK1 ceRNA networks.
Hu R; Chen S; Yan J
J Orthop Surg Res; 2021 May; 16(1):300. PubMed ID: 33962616
[TBL] [Abstract][Full Text] [Related]
13. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
[TBL] [Abstract][Full Text] [Related]
14. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.
Pai S; Yadav VK; Kuo KT; Pikatan NW; Lin CS; Chien MH; Lee WH; Hsiao M; Chiu SC; Yeh CT; Tsai JT
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768921
[No Abstract] [Full Text] [Related]
15. Inhibition of pyruvate dehydrogenase kinase‑1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming.
Xu H; He Y; Ma J; Zhao Y; Liu Y; Sun L; Su J
Int J Oncol; 2020 Sep; 57(3):733-742. PubMed ID: 32705170
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-4290 suppresses PDK1-mediated glycolysis to enhance the sensitivity of gastric cancer cell to cisplatin.
Qian Y; Wu X; Wang H; Hou G; Han X; Song W
Braz J Med Biol Res; 2020; 53(5):e9330. PubMed ID: 32321153
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides as pyruvate dehydrogenase kinase 1 (PDK1) inhibitors to reduce the growth of cancer cells.
Zhang SL; Zhang W; Yang Z; Hu X; Tam KY
Eur J Pharm Sci; 2017 Dec; 110():87-92. PubMed ID: 28347773
[TBL] [Abstract][Full Text] [Related]
18. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
Zhou Y; Guo Y; Ran M; Shan W; Granchi C; Giovannetti E; Minutolo F; Peters GJ; Tam KY
Cancer Lett; 2023 Nov; 577():216425. PubMed ID: 37805163
[TBL] [Abstract][Full Text] [Related]
20. Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
Sriskandarajah P; De Haven Brandon A; MacLeod K; Carragher NO; Kirkin V; Kaiser M; Whittaker SR
BMC Cancer; 2020 Mar; 20(1):269. PubMed ID: 32228485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
